Invitae
Invitae to Acquire Consumer Health Tech Firm Ciitizen for $325M
The company focused on aggregating genomic content in one service believes Ciitizen will enhance its goal by enabling patients to aggregate and share their data to improve healthcare.
Jury Awards ArcherDx, MGH $4.7M in Qiagen Patent Infringement Lawsuit
A federal jury ruled that various Qiagen sample prep products infringe a pair of US patents underlying ArcherDx's anchored multiplex PCR technology.
Top Five Articles on 360Dx Last Week: CDC Withdraws EUA Test; Qiagen Gets EUA for Antigen Test; More
Last week, readers were most interested in the CDC's EUA withdrawal for its SARS-CoV-2 detection test, and Qiagen receiving EUA for its rapid portable antigent test.
Invitae Writes off $262.5M Liability Upon Failure to Meet Regulatory Milestone
The company still expects the Stratafide cancer test to achieve FDA approval or clearance, but after March 31, 2022.
Invitae More Than Doubles Q2 Revenues
The company reported $116.3 million in revenues compared to $46.2 million a year ago, which exceeded Wall Street expectations.
May 4, 2021
Invitae Q1 Revenues Increase 61 Percent
Feb 17, 2021
Invitae Q4 2020 Revenues Increase 51 Percent
Feb 1, 2021
Oppenheimer Downgrades Invitae to Perform Rating
Jan 22, 2021
Invitae Prices $400M Common Stock Offering
Jan 20, 2021
Invitae to Raise $400M in Proposed Public Offering
Jan 11, 2021